$8.89
8.58% today
Nasdaq, Sep 16, 08:16 pm CET
ISIN
US0465131078
Symbol
ATRA
Sector
Industry

Atara Biotherapeutics Inc Stock price

$9.72
+1.70 21.20% 1M
-6.96 41.71% 6M
-3.10 24.18% YTD
-27.28 73.73% 1Y
-392.03 97.58% 3Y
-369.28 97.44% 5Y
-256.53 96.35% 10Y
Nasdaq, Closing price Fri, Sep 13 2024
+1.64 20.30%
ISIN
US0465131078
Symbol
ATRA
Sector
Industry

Key metrics

Market capitalization $55.15m
Enterprise Value $109.54m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.76
P/S ratio (TTM) P/S ratio 0.88
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 809.03%
Revenue (TTM) Revenue $62.39m
EBIT (operating result TTM) EBIT $-167.26m
Free Cash Flow (TTM) Free Cash Flow $-142.49m
Cash position $35.44m
EPS (TTM) EPS $-39.12
P/E forward negative
P/S forward 0.54
EV/Sales forward 1.07
Short interest 8.47%
Show more

Is Atara Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

Atara Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Atara Biotherapeutics Inc forecast:

2x Buy
40%
2x Hold
40%
1x Sell
20%

Analyst Opinions

5 Analysts have issued a Atara Biotherapeutics Inc forecast:

Buy
40%
Hold
40%
Sell
20%

Financial data from Atara Biotherapeutics Inc

Jun '24
+/-
%
Net Profit -181 -181
41% 41%
-290%
Depreciation and Amortization 5.14 5.14
69% 69%
8%
Stock Compensation 36 36
28% 28%
57%
Operating Cash Flow -142 -142
30% 30%
-228%
Investments 0.48 0.48
55% 55%
1%
Dividend Paid - -
-
-
Free Cash Flow -142 -142
30% 30%
-228%

In millions USD.

Don't miss a Thing! We will send you all news about Atara Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Atara Biotherapeutics Inc Stock News

Neutral
Business Wire
10 days ago
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,700 restricted stock units of Atara's common stock to one newly hired empl...
Neutral
Business Wire
12 days ago
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Cokey Nguyen, Ph.D., Executive Vice President, Chief Scientific & Technical Officer...
Neutral
Business Wire
about one month ago
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2024, recent business highlights, and key upcomi...
More Atara Biotherapeutics Inc News

Company Profile

Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.

Head office United States
CEO Anhco Nguyen
Employees 225
Founded 2012
Website www.atarabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today